Summary: FDA clears optical coherence tomography device for esophagus, allowing physicians to see more esophageal tissue for biopsy and treatment procedures, providing them with valuable imaging information.
- NvisionVLE Imaging System
April 26, 2013 - The NvisionVLE Imaging System is the first volumetric, optical coherence tomography (OCT) device with 510(k) clearance from the Food and Drug Administration (FDA) for endoscopic imaging, and now imaging of esophageal tissue microstructure.
NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure by providing 2-dimensional, cross-sectional, real-time depth visualization. The technology behind the NvisionVLE, a variation of Fourier-domain OCT, known as OFDI (optical frequency-domain imaging), was developed at Massachusetts General Hospital.
“We believe that the NvisionVLE Imaging System will allow physicians to see more esophageal tissue for biopsy and treatment procedures, providing them with valuable imaging information,” said Charles Carignan, MD, president and chief executive officer of NinePoint Medical.
The company is running a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus using the NvisionVLE Imaging System. Barrett’s esophagus is one of the most common precursors to esophageal adenocarcinoma, the fastest growing cancer in the Western world.
For more information: www.ninepointmedical.com and www.appliedradiology.com